Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Neuropharmacology. 2014 Apr 26;84:1–12. doi: 10.1016/j.neuropharm.2014.04.011

Figure 4. The role of S6K and the proteasome in mGluR-LTD induction was altered after ELS.

Figure 4

A, The S6K inhibitor PF-4708671 (25 µM) completely blocked mGluR-LTD in controls, yet mGluR-LTD was still present in ELS rats (control: 106.14. ± 9.71%, n = 6, ELS: 54.96±8.75%, n = 10, P < 0.01, Student’s t-test). B, The proteasomal inhibitor MG-132 (10 µM) completely blocked mGluR-LTD in controls, yet mGluR-LTD was still present in ELS rats (control: 99.93 ± 6.05%, n = 8, ELS: 62.93 ± 7.83%, n = 6, P = 0.0025, Student’s t-test). Insets show averages of 4 fEPSPs near the numerically indicated time points. Scale bar 0.5 mV × 15 ms. Dashed line indicates baseline; dashed/dotted line indicates average control mGluR-LTD (vehicle, no inhibitors); dotted line indicates average ELS mGluR-LTD (vehicle, no inhibitors).